A father-son biotech saga
Remember Neurochem? STAT's Adam Feuerstein does. A dozen years ago, Neurochem was running a Phase 3 trial on a treatment for Alzheimer’s disease that CEO Francesco Bellini was convinced would succeed. But, like most drugs with similar aims, it did not, and after that failure, Neurochem faded from view.
But it didn't die. The company has since become Bellus Health, and while its CEO has since retired, there's another Bellini in his place, a son named Roberto. Bellus has ditched Alzheimer's in favor of chronic cough and is now plotting to start a mid-stage trial later this year.
Read more.
.png)
No hay comentarios:
Publicar un comentario